ICU Medical (NASDAQ:ICUI) reported Q2 EPS of $1.37, $0.49 worse than the analyst estimate of $1.86. Revenue for the quarter came in at $561 million versus the consensus estimate of $566.47 million.
GUIDANCE:
ICU Medical sees FY2022 EPS of $6.20-$6.80, versus the consensus of $9.17.
- The Company is updating its full year 2022 guidance of adjusted EBITDA from a range of $450 million to $500 million to a range of $350 million to $370 million and adjusted diluted earnings per share from a range of $9.00 to $10.50 to a range of $6.20 to $6.80.